Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-920 for Refractory Systemic Lupus Erythematosus
NCT06340750Phase 1Recruiting
- Sponsor
- Luminary Therapeutics
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAFF CAR-T in systemic lupus erythematosus (SLE), sponsored by Luminary Therapeutics. Primary endpoints: Safety of the Treatment at 5 years and Recommended Phase 2 Dose at 5 years. Started Apr 2025; status: recruiting.
02
Drugs
BAFF CAR-T
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06340750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340750.